Praxis Precision Medicines, Inc. (PRAX) Form 8-K — Aug 6, 2026
Praxis Precision Medicines reported second quarter 2026 results anchored by two FDA de-riskings: mid-cycle reviews for ulixacaltamide (Essential Tremor, PDUFA January 29, 2027) and relutrigine (SCN2A/SCN8A DEEs, PDUFA December 27, 2026) identified no major safety or efficacy concerns to date, and the agency confirmed no advisory committee meetings are planned for either application. The company held approximately $1.4 billion in cash, cash equivalents and marketable securities at June 30, 2026, up $447.8 million from $926.1 million at year-end 2025, driven by its January 2026 follow-on offering and interest income, funding operations into 2028.
Key figures
- Guidance
- Cash, cash equivalents and marketable securities expected to fund operations into 2028
- Total Assets
- 1390102000
- Cash Position
- approximately $1.4 billion ($474.8M cash and cash equivalents + $899.1M marketable securities) as of June 30, 2026
- Shares Outstanding
- 27900000
- Cash Increase
- $447.8 million, primarily from January 2026 follow-on offering and interest income
- Net Loss Q2 2025
- $71.1 million (including $7.8 million stock-based compensation)
- Cash Prior Period
- $926.1 million as of December 31, 2025
- Ga Expense Q2 2026
- $27.5 million (vs. $13.1 million in Q2 2025)
- Relutrigine Pdufa
- December 27, 2026
- Emerald Enrollment
- approximately 200 patients across more than 50 genetically defined etiologies; topline Q4 2026
- Rnd Expense Q2 2026
- $69.4 million (vs. $63.0 million in Q2 2025)
- Ulixacaltamide Pdufa
- January 29, 2027
- Et Patient Population US
- approximately 7 million
- Stock Compensation Q2 2026
- $11.3 million
- Portfolio Peak Sales Potential
- >$20 billion (company estimate across four late-stage assets)
Price after filing
Close on the filing date to close N calendar days later (from $310.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.